Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping Mounjaro suddenly is medically safe in that there is no physical withdrawal syndrome the way there is with some medicines — you won't experience dangerous rebound effects. What the evidence does show, clearly and consistently, is that the appetite-regulating effects of tirzepatide reverse after stopping, and much of the weight lost during treatment tends to return over the following months. That is the honest, practical answer to whether you can stop Mounjaro suddenly: you can, but there are real consequences worth understanding before you decide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest evidence comes from SURMOUNT-4, a withdrawal extension of the tirzepatide programme. Participants who had reached their lowest weight on tirzepatide were re-randomised: one group continued the medicine, the other switched to placebo. Within 52 weeks of stopping, the placebo group had regained around two thirds of the weight they had lost. The group who continued treatment maintained and slightly extended their results.
This pattern is not unique to tirzepatide. The biology is consistent: GLP-1 and GIP receptor agonists work while they are active in your system, suppressing appetite and slowing gastric emptying. Once you stop (whether gradually or abruptly) those mechanisms switch off. Hunger returns to its pre-treatment baseline, sometimes within days. The NICE appraisal of tirzepatide (TA1026) acknowledges this weight-regain trajectory when framing long-term treatment decisions.
None of that means stopping is wrong. It means stopping is a decision with predictable consequences, and knowing them upfront lets you plan. If you want a broader picture of how the medicine works before making any decision, the tirzepatide overview covers the mechanism in plain language.
From a purely pharmacological standpoint, tirzepatide does not require a taper to avoid harm. There is no rebound hypertension, no seizure risk, no hormonal crash of the kind associated with corticosteroids or certain antidepressants. So if you had to stop today (a planned surgery, a stock issue, a change in health circumstances) your body will not be in danger from the abruptness itself.
The one practical consideration is gastrointestinal. Some people find that appetite returns sharply after abrupt stopping, which can lead to eating patterns that feel uncomfortable or hard to manage. A prescriber might suggest a stepped reduction for this reason, not a safety one. There is a meaningful difference between 'can I stop Mounjaro suddenly without physical harm' (yes) and 'is an abrupt stop the best-managed exit' (often not).
People sometimes ask about pausing treatment rather than stopping entirely. That is a different question, stopping Mounjaro for a week has its own considerations, and restarting after a gap may require returning to a lower dose. Your prescriber is the right person to map that out.
The NHS notes, in its guidance on tirzepatide, that weight management medicines work best alongside sustained changes to diet and activity. That framing matters here: people who have built strong habits during treatment tend to regain less weight after stopping than those who relied on the medicine alone.
It is worth doing a quick honest audit before you stop, just a minute with a notebook. Write down what your typical day of eating looks like now versus before treatment started. If the two pictures look similar, appetite returning is likely to push you back toward the earlier pattern fairly quickly. If they look genuinely different, the lifestyle work you have done gives you a real buffer.
Cost sometimes drives the question of stopping, and it is fair to look at that directly. If you're weighing up whether to continue private treatment, our Mounjaro price comparison guide sets out what the UK market actually looks like and what a full private prescription legitimately includes. That may help you decide whether continuing with support is workable, or whether stopping is the right call for now.
If you do want to understand stopping in more depth (including the difference between a planned end to treatment and an unplanned break) the question of how to stop Mounjaro safely is covered in detail on its own page.
At nume, every repeat order goes back to a clinician before it is approved. That structure exists partly for this reason: a prescriber who knows your history can spot when stopping is the right move (and can advise on how to do it in a way that fits your situation) rather than you simply running out of pens and stopping by default.
Stopping by default is probably the least good option. You lose the medicine's effect with no plan for what follows. Appetite returning without any preparation is harder to manage than appetite returning when you have thought about it in advance with a clinician.
The Mounjaro treatment page covers what a full treatment journey looks like, including when continuing, pausing, or stopping might come up at a clinical review. If you have a specific situation in mind (a break, a dose change, or a concern about whether continued treatment is appropriate for you) our team at nume can review it properly. There is also a broader look at stopping and restarting Mounjaro if you are thinking about treatment as something you might return to later rather than ending permanently.
If you have a question before committing to a consultation, the FAQs cover many of the common ones. And when you are ready to speak to someone clinical about your next step, our prescribers are available seven days a week, start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.